Goserelin (Zoladex®)

Common name: Goserelin
Brand name: Zoladex®
 

What is Goserelin?

Goserelin is a hormonal therapy used to treat advanced prostate cancer by blocking the production or action of luteinizing hormone releasing hormone (LHRH) which reduces the levels of testosterone in the body.

Goserelin is used:
  • in the palliative treatment of patients with hormone-dependent advanced prostate cancer.
  • in combination with non-steroidal anti-androgens and radiation therapy for treating locally advanced prostate cancer.
  • as an adjuvant hormone therapy to external beam irradiation for locally advanced prostate cancer.


How is Goserelin administered?

Goserelin is administered by subcutaneous injection.


What are possible side effects of this treatment?

Everyone responds differently to hormone therapy – some experience many side effects while others experience very few. Below are some side effects experienced by those who received goserelin. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
  • Breast tenderness
  • Changes to mood
  • Decreased sex drive (low libido)
  • Fatigue
  • Hot flashes
  • Impotence
  • Nausea / vomiting
  • Osteoporosis (weakened bones)
  • Rashes
  • Sore joints
  • Weight gain
 

Is Goserelin covered in my province or territory?

Goserelin is covered by all provincial/territorial drug programs.
 
Last Reviewed: July 2017

Donate Now!




Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Prostate Cancer Canada and the Movember Foundation Announce $4M in Research Grants

Toronto, October 23, 2018 – Prostate Cancer Canada and the Movember Foundation today announced $4 million in funding to three Canadian researchers to predict how well prostate cancer will respond to treatment, based on men’s biological markers, specifically in their tumour cells and blood – opening a path to more personalized care with fewer side effects and a better chance of survival.
More

Gay and bisexual men living with prostate cancer focus of research

Vancouver, September 25, 2018 – Research funded by Prostate Cancer Canada is preparing the way to improve quality of life for men-who-have-sex-with-men (MSM)1 in the LGBTQ2+ community.
More

Prostate Cancer Canada launches first national program in radioligand therapy

Toronto, June 27, 2018 – Canadian researchers are leading the future of treatment for men with advanced prostate cancer in this country, with a new Prostate Cancer Canada grant funded by the Movember Foundation.
More


Click here for news archive